SynthesisBMC infectious diseases2026
Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this network meta-analysis was to evaluate and compare the efficacy and safety of different antimicrobial regimens used in the treatment of pneumonia caused by extensively drug-resistant (XDR) or multidrug-resistant (MDR) Acinetobacter baumannii (AB). Given the increasing prevalence of resistant strains, identifying optimal treatment strategies is crucial. MATERIALS AND
methodsWe systematically analyzed data from randomized controlled trials and retrospective cohort studies retrieved from major electronic databases. The included studies evaluated all-cause mortality, clinical success, microbiological eradication, and nephrotoxicity associated with cefiderocol, intravenous (IV) colistin, inhaled colistin, igecycline, sulbactam, and their combination-based regimens in patients with MDR/XDR-AB pneumonia.
resultsA total of 19 eligible studies involving 1,941 participants were included in the analysis. Cefiderocol-containing regimens demonstrated the greatest reduction in all-cause mortality (odds ratio (OR): 0.24; 95% CI: 0.09-0.68) compared to other therapies. In terms of clinical success, cefiderocol-containing regimens (OR: 2.77; 95% CI: 1.07-7.19) and inhaled colistin (OR: 2.61; 95% CI: 1.14-5.99) were significantly more effective than other regimens. Microbiological eradication was most notable with inhaled colistin, and with IV colistin combined with sulbactam or tigecycline. However, nephrotoxicity was commonly observed with IV colistin, while tigecycline monotherapy showed the lowest nephrotoxicity risk (OR: 0.15; 95% CI: 0.04-0.60).
conclusionThis study provides comprehensive evidence on current and emerging treatments for MDR/XDR-AB pneumonia. Cefiderocol-containing regimens appears to be the most effective regimen in reducing mortality and improving clinical outcomes, though nephrotoxicity risks must be carefully considered when using IV colistin-based therapies. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.